ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.90
      0.14%
      Bitcoin
      65,127.98
      -0.02%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      06/16/20234:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/15/20232:11PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      06/07/20232:00PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/07/202311:00AMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:INCYIncyte Corporation
      05/26/20233:38AMBusiness WireDonnées du portefeuille d'oncologie d'Incyte acceptées pour une présentation à la réunion annuelle 2023 de l'ASCO et au congrès hybride EHA2023NASDAQ:INCYIncyte Corporation
      05/26/20233:05AMBusiness WireDaten aus dem Onkologie-Portfolio von Incyte werden beim Jahrestreffen 2023 der ASCO und beim EHA2023 Hybrid Congress präsentiertNASDAQ:INCYIncyte Corporation
      05/25/20235:01PMBusiness WireData from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid CongressNASDAQ:INCYIncyte Corporation
      05/23/20238:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      05/08/20235:22PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      05/08/20238:30AMBusiness WireIncyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership RoleNASDAQ:INCYIncyte Corporation
      05/02/20234:04PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INCYIncyte Corporation
      05/02/20237:00AMBusiness WireIncyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      05/01/20233:00PMBusiness WireIncyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) CreamNASDAQ:INCYIncyte Corporation
      04/28/20238:04AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:INCYIncyte Corporation
      04/28/20238:02AMEdgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:INCYIncyte Corporation
      04/28/20238:02AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:INCYIncyte Corporation
      04/21/202311:45AMBusiness WireIncyte annonce l'approbation de la Commission européenne pour la crème Opzelura® (ruxolitinib) dans le traitement du vitiligo non segmentaire avec atteinte du visage chez l'adulte et l'adolescentNASDAQ:INCYIncyte Corporation
      04/21/202312:28AMBusiness WireIncyte meldet EU-Zulassung für Opzelura® (Ruxolitinib) Creme zur Behandlung von nichtsegmentaler Vitiligo mit Gesichtsbeteiligung bei Erwachsenen und JugendlichenNASDAQ:INCYIncyte Corporation
      04/20/202310:21AMBusiness WireIncyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and AdolescentsNASDAQ:INCYIncyte Corporation
      04/18/20238:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      04/17/20237:37AMBusiness WireAprès cinq ans, MorphoSys et Incyte annoncent les résultats de l'étude L-MIND montrant des réponses prolongées et durables chez des patients atteints de LDGCB récidivant ou réfractaire traités par Monjuvi® (tafasitamab-cxix)NASDAQ:INCYIncyte Corporation
      04/17/20237:37AMBusiness WireMorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigenNASDAQ:INCYIncyte Corporation
      04/16/20233:01PMBusiness WireMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)NASDAQ:INCYIncyte Corporation
      04/11/20238:00AMBusiness WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      04/04/20234:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      04/04/20234:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      03/28/20237:53AMBusiness Wireインサイト、「ペマジール®」（ペミガチニブ）が骨髄／リンパ性腫瘍（MLN）患者の治療薬として日本で承認されたと発表NASDAQ:INCYIncyte Corporation
      03/27/202310:36AMBusiness WireIncyte annonce l'autorisation du Pemazyre® (pemigatinib) au Japon pour le traitement des patients atteints de néoplasmes myéloïdes/lymphoïdes (NML)NASDAQ:INCYIncyte Corporation
      03/27/20237:11AMBusiness WireIncyte gibt japanische Zulassung von Pemazyre® (Pemigatinib) für die Behandlung von Patienten mit myeloischen/lymphoiden Neoplasien (MLN) bekanntNASDAQ:INCYIncyte Corporation
      03/27/20232:00AMBusiness WireIncyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)NASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY